Austco Healthcare (AHC) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 Oct, 2026Opening remarks and agenda
Agenda covered the Chairman’s address, CEO presentation, stakeholder questions and formal resolutions; all resolutions were voted on by poll.
Quorum was confirmed, Peter Renda of Computershare Investor Services was appointed Returning Officer, and CEO Clayton Astles outlined a strategy to win facilities and grow with them worldwide across 5,000+ facilities.
Financial performance review
FY26 revenue was AUD 94.2m, up 15.8%; EBITDA was AUD 14.9m, up 14%; profit before tax was AUD 11.6m, up 43.8%; NPAT was AUD 9.0m, up 51.8%.
Gross margin rose 140bp to 53.4%; EBITDA margin was 15.8% versus 16%, reflecting the full-year cost of three acquired businesses and continued investment in people.
Software and maintenance revenue grew 19% to AUD 11.4m, or 12% of revenue.
Operating cash flow was AUD 12.5m; cash was AUD 16.3m at 30 June 2026, versus AUD 14.5m at June 2025, with no material borrowings.
Unfilled contracted revenue was AUD 51.2m at 17 August 2026, up 13% since June; year-end movement reflected currency translation, not lost work.
Board and executive committee updates
Effective 1 October 2026, Brett Burns became Audit and Risk Management Committee Chair, succeeding Graeme Billings; Tony Glenning succeeded Burns as Nomination and Remuneration Committee Chair.
Billings committed to serving his current three-year term in full but did not say whether he would seek another term in 2028.
Latest events from Austco Healthcare
- Record revenue, profit, and recurring software growth, with strong cash and major contract wins.AHC
H2 2026 - Record revenue and profit growth driven by contracts, acquisitions, and software innovation.AHC
Investor presentation - Record revenue, profit, and software growth driven by acquisitions and innovation.AHC
Investor presentation - Record revenue and EBITDA growth, global expansion, and strong cash position drive future outlook.AHC
Investor presentation - Record revenue and profit growth, with strong order backlog and positive growth outlook.AHC
H2 2024 - Record Q1 revenue growth and major contract wins drive strong outlook for continued expansion.AHC
Q1 2025 TU - First-half FY25 revenue and EBITDA are set to surge, boosted by acquisitions and organic growth.AHC
Q2 2025 TU - Record revenue and EBITDA growth, strong profit, and robust order book support future performance.AHC
H1 2025 - Revenue and EBITDA surged year-over-year, with strong cash flow and robust contracted revenue.AHC
Q4 2025 TU